A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care.
Identifieur interne : 001A04 ( Main/Exploration ); précédent : 001A03; suivant : 001A05A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care.
Auteurs : Joshua D. Lee ; Charles D. Burger [États-Unis] ; Genecelle B. Delossantos ; Daniel Grinnan [États-Unis] ; David D. Ralph ; Sam G. Rayner ; John J. Ryan [États-Unis] ; Zeenat Safdar [États-Unis] ; Corey E. Ventetuolo [États-Unis] ; Roham T. Zamanian [États-Unis] ; Peter J. Leary [États-Unis]Source :
- Annals of the American Thoracic Society [ 2325-6621 ] ; 2020.
Descripteurs français
- KwdFr :
- AMP (analogues et dérivés), AMP (usage thérapeutique), Alanine (analogues et dérivés), Alanine (usage thérapeutique), Angiographie par tomodensitométrie (statistiques et données numériques), Anticorps monoclonaux humanisés (usage thérapeutique), Antiviraux (usage thérapeutique), Azithromycine (usage thérapeutique), Cathétérisme cardiaque (statistiques et données numériques), Chloroquine (usage thérapeutique), Embolie pulmonaire (complications), Embolie pulmonaire (diagnostic), Embolie pulmonaire (thérapie), Embolie pulmonaire (épidémiologie), Enquêtes et questionnaires (MeSH), Hormones corticosurrénaliennes (usage thérapeutique), Hospitalisation (MeSH), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Hypertension pulmonaire (diagnostic), Hypertension pulmonaire (thérapie), Hypertension pulmonaire (épidémiologie), Hypertension pulmonaire (étiologie), Immunisation passive (MeSH), Incidence (MeSH), Maladie chronique (MeSH), Mortalité hospitalière (MeSH), Prestations des soins de santé (MeSH), Télémédecine (statistiques et données numériques), Unités de soins intensifs (MeSH), Échocardiographie (statistiques et données numériques), États-Unis (épidémiologie).
- MESH :
- analogues et dérivés : AMP, Alanine.
- diagnostic : Embolie pulmonaire, Hypertension pulmonaire.
- statistiques et données numériques : Angiographie par tomodensitométrie, Cathétérisme cardiaque, Télémédecine, Échocardiographie.
- thérapie : Embolie pulmonaire, Hypertension pulmonaire.
- usage thérapeutique : AMP, Alanine, Anticorps monoclonaux humanisés, Antiviraux, Azithromycine, Chloroquine, Embolie pulmonaire, Hormones corticosurrénaliennes, Hydroxychloroquine.
- épidémiologie : Embolie pulmonaire, Hypertension pulmonaire, États-Unis.
- étiologie : Hypertension pulmonaire.
- Enquêtes et questionnaires, Hospitalisation, Humains, Immunisation passive, Incidence, Maladie chronique, Mortalité hospitalière, Prestations des soins de santé, Unités de soins intensifs.
- Wicri :
- geographic : États-Unis.
English descriptors
- KwdEn :
- Adenosine Monophosphate (analogs & derivatives), Adenosine Monophosphate (therapeutic use), Adrenal Cortex Hormones (therapeutic use), Alanine (analogs & derivatives), Alanine (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Antiviral Agents (therapeutic use), Azithromycin (therapeutic use), COVID-19 (drug therapy), COVID-19 (epidemiology), COVID-19 (therapy), Cardiac Catheterization (statistics & numerical data), Chloroquine (therapeutic use), Chronic Disease (MeSH), Computed Tomography Angiography (statistics & numerical data), Delivery of Health Care (MeSH), Echocardiography (statistics & numerical data), Hospital Mortality (MeSH), Hospitalization (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Hypertension, Pulmonary (diagnosis), Hypertension, Pulmonary (epidemiology), Hypertension, Pulmonary (etiology), Hypertension, Pulmonary (therapy), Immunization, Passive (MeSH), Incidence (MeSH), Intensive Care Units (MeSH), Pulmonary Arterial Hypertension (diagnosis), Pulmonary Arterial Hypertension (epidemiology), Pulmonary Arterial Hypertension (therapy), Pulmonary Embolism (complications), Pulmonary Embolism (diagnosis), Pulmonary Embolism (epidemiology), Pulmonary Embolism (therapy), Surveys and Questionnaires (MeSH), Telemedicine (statistics & numerical data), United States (epidemiology).
- MESH :
- chemical , analogs & derivatives : Adenosine Monophosphate, Alanine.
- chemical , therapeutic use : Adenosine Monophosphate, Adrenal Cortex Hormones, Alanine, Antibodies, Monoclonal, Humanized, Antiviral Agents, Azithromycin, Chloroquine, Hydroxychloroquine.
- geographic , epidemiology : United States.
- complications : Pulmonary Embolism.
- diagnosis : Hypertension, Pulmonary, Pulmonary Arterial Hypertension, Pulmonary Embolism.
- drug therapy : COVID-19.
- epidemiology : COVID-19, Hypertension, Pulmonary, Pulmonary Arterial Hypertension, Pulmonary Embolism.
- etiology : Hypertension, Pulmonary.
- statistics & numerical data : Cardiac Catheterization, Computed Tomography Angiography, Echocardiography, Telemedicine.
- therapy : COVID-19, Hypertension, Pulmonary, Pulmonary Arterial Hypertension, Pulmonary Embolism.
- Chronic Disease, Delivery of Health Care, Hospital Mortality, Hospitalization, Humans, Immunization, Passive, Incidence, Intensive Care Units, Surveys and Questionnaires.
Abstract
Rationale: Patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) typically undergo frequent clinical evaluation. The incidence and outcomes of coronavirus disease (COVID-19) and its impact on routine management for patients with pulmonary vascular disease is currently unknown.Objectives: To assess the cumulative incidence and outcomes of recognized COVID-19 for patients with PAH/CTEPH followed at accredited pulmonary hypertension centers, and to evaluate the pandemic's impact on clinic operations at these centers.Methods: A survey was e-mailed to program directors of centers accredited by the Pulmonary Hypertension Association. Descriptive analyses and linear regression were used to analyze results.Results: Seventy-seven center directors were successfully e-mailed a survey, and 58 responded (75%). The cumulative incidence of COVID-19 recognized in individuals with PAH/CTEPH was 2.9 cases per 1,000 patients, similar to the general U.S. population. In patients with PAH/CTEPH for whom COVID-19 was recognized, 30% were hospitalized and 12% died. These outcomes appear worse than the general population. A large impact on clinic operations was observed including fewer clinic visits and substantially increased use of telehealth. A majority of centers curtailed diagnostic testing and a minority limited new starts of medical therapy. Most centers did not use experimental therapies in patients with PAH/CTEPH diagnosed with COVID-19.Conclusions: The cumulative incidence of COVID-19 recognized in patients with PAH/CTEPH appears similar to the broader population, although outcomes may be worse. Although the total number of patients with PAH/CTEPH recognized to have COVID-19 was small, the impact of COVID-19 on broader clinic operations, testing, and treatment was substantial.
DOI: 10.1513/AnnalsATS.202005-521OC
PubMed: 32726561
PubMed Central: PMC7706604
Affiliations:
- États-Unis
- Californie, Floride, Rhode Island, Texas, Utah, Virginie, Washington (État)
- Providence (Rhode Island), Seattle, Stanford (Californie)
- Université Brown, Université Stanford, Université de Washington
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care.</title>
<author><name sortKey="Lee, Joshua D" sort="Lee, Joshua D" uniqKey="Lee J" first="Joshua D" last="Lee">Joshua D. Lee</name>
<affiliation><nlm:affiliation>Department of Medicine and.</nlm:affiliation>
<wicri:noCountry code="no comma">Department of Medicine and.</wicri:noCountry>
<wicri:noCountry code="no comma">Department of Medicine and.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Burger, Charles D" sort="Burger, Charles D" uniqKey="Burger C" first="Charles D" last="Burger">Charles D. Burger</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pulmonary Medicine, Mayo Clinic Florida, Jacksonville, Florida.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
<wicri:cityArea>Department of Pulmonary Medicine, Mayo Clinic Florida, Jacksonville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Delossantos, Genecelle B" sort="Delossantos, Genecelle B" uniqKey="Delossantos G" first="Genecelle B" last="Delossantos">Genecelle B. Delossantos</name>
<affiliation><nlm:affiliation>Department of Medicine and.</nlm:affiliation>
<wicri:noCountry code="no comma">Department of Medicine and.</wicri:noCountry>
<wicri:noCountry code="no comma">Department of Medicine and.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Grinnan, Daniel" sort="Grinnan, Daniel" uniqKey="Grinnan D" first="Daniel" last="Grinnan">Daniel Grinnan</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Virginia Commonwealth University, Richmond, Virginia.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Virginie</region>
</placeName>
<wicri:cityArea>Department of Medicine, Virginia Commonwealth University, Richmond</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Ralph, David D" sort="Ralph, David D" uniqKey="Ralph D" first="David D" last="Ralph">David D. Ralph</name>
<affiliation><nlm:affiliation>Department of Medicine and.</nlm:affiliation>
<wicri:noCountry code="no comma">Department of Medicine and.</wicri:noCountry>
<wicri:noCountry code="no comma">Department of Medicine and.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Rayner, Sam G" sort="Rayner, Sam G" uniqKey="Rayner S" first="Sam G" last="Rayner">Sam G. Rayner</name>
<affiliation><nlm:affiliation>Department of Medicine and.</nlm:affiliation>
<wicri:noCountry code="no comma">Department of Medicine and.</wicri:noCountry>
<wicri:noCountry code="no comma">Department of Medicine and.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Ryan, John J" sort="Ryan, John J" uniqKey="Ryan J" first="John J" last="Ryan">John J. Ryan</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of Utah, Salt Lake City, Utah.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Utah</region>
</placeName>
<wicri:cityArea>Department of Medicine, University of Utah, Salt Lake City</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Safdar, Zeenat" sort="Safdar, Zeenat" uniqKey="Safdar Z" first="Zeenat" last="Safdar">Zeenat Safdar</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Baylor College of Medicine, Houston, Texas.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>Department of Medicine, Baylor College of Medicine, Houston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Ventetuolo, Corey E" sort="Ventetuolo, Corey E" uniqKey="Ventetuolo C" first="Corey E" last="Ventetuolo">Corey E. Ventetuolo</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine and Health Services, Policy and Practice, Brown University, Providence, Rhode Island; and.</nlm:affiliation>
<orgName type="university">Université Brown</orgName>
<country>États-Unis</country>
<placeName><settlement type="city">Providence (Rhode Island)</settlement>
<region type="state">Rhode Island</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zamanian, Roham T" sort="Zamanian, Roham T" uniqKey="Zamanian R" first="Roham T" last="Zamanian">Roham T. Zamanian</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, Stanford University, Stanford, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
<settlement type="city">Stanford (Californie)</settlement>
</placeName>
<wicri:cityArea>Department of Medicine, Stanford University, Stanford</wicri:cityArea>
<orgName type="university">Université Stanford</orgName>
</affiliation>
</author>
<author><name sortKey="Leary, Peter J" sort="Leary, Peter J" uniqKey="Leary P" first="Peter J" last="Leary">Peter J. Leary</name>
<affiliation><nlm:affiliation>Department of Medicine and.</nlm:affiliation>
<wicri:noCountry code="no comma">Department of Medicine and.</wicri:noCountry>
<wicri:noCountry code="no comma">Department of Medicine and.</wicri:noCountry>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Department of Epidemiology, University of Washington, Seattle, Washington.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Washington (État)</region>
<settlement type="city">Seattle</settlement>
</placeName>
<wicri:cityArea>Department of Epidemiology, University of Washington, Seattle</wicri:cityArea>
<orgName type="university">Université de Washington</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32726561</idno>
<idno type="pmid">32726561</idno>
<idno type="doi">10.1513/AnnalsATS.202005-521OC</idno>
<idno type="pmc">PMC7706604</idno>
<idno type="wicri:Area/Main/Corpus">001039</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001039</idno>
<idno type="wicri:Area/Main/Curation">001039</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001039</idno>
<idno type="wicri:Area/Main/Exploration">001039</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care.</title>
<author><name sortKey="Lee, Joshua D" sort="Lee, Joshua D" uniqKey="Lee J" first="Joshua D" last="Lee">Joshua D. Lee</name>
<affiliation><nlm:affiliation>Department of Medicine and.</nlm:affiliation>
<wicri:noCountry code="no comma">Department of Medicine and.</wicri:noCountry>
<wicri:noCountry code="no comma">Department of Medicine and.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Burger, Charles D" sort="Burger, Charles D" uniqKey="Burger C" first="Charles D" last="Burger">Charles D. Burger</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pulmonary Medicine, Mayo Clinic Florida, Jacksonville, Florida.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
<wicri:cityArea>Department of Pulmonary Medicine, Mayo Clinic Florida, Jacksonville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Delossantos, Genecelle B" sort="Delossantos, Genecelle B" uniqKey="Delossantos G" first="Genecelle B" last="Delossantos">Genecelle B. Delossantos</name>
<affiliation><nlm:affiliation>Department of Medicine and.</nlm:affiliation>
<wicri:noCountry code="no comma">Department of Medicine and.</wicri:noCountry>
<wicri:noCountry code="no comma">Department of Medicine and.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Grinnan, Daniel" sort="Grinnan, Daniel" uniqKey="Grinnan D" first="Daniel" last="Grinnan">Daniel Grinnan</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Virginia Commonwealth University, Richmond, Virginia.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Virginie</region>
</placeName>
<wicri:cityArea>Department of Medicine, Virginia Commonwealth University, Richmond</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Ralph, David D" sort="Ralph, David D" uniqKey="Ralph D" first="David D" last="Ralph">David D. Ralph</name>
<affiliation><nlm:affiliation>Department of Medicine and.</nlm:affiliation>
<wicri:noCountry code="no comma">Department of Medicine and.</wicri:noCountry>
<wicri:noCountry code="no comma">Department of Medicine and.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Rayner, Sam G" sort="Rayner, Sam G" uniqKey="Rayner S" first="Sam G" last="Rayner">Sam G. Rayner</name>
<affiliation><nlm:affiliation>Department of Medicine and.</nlm:affiliation>
<wicri:noCountry code="no comma">Department of Medicine and.</wicri:noCountry>
<wicri:noCountry code="no comma">Department of Medicine and.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Ryan, John J" sort="Ryan, John J" uniqKey="Ryan J" first="John J" last="Ryan">John J. Ryan</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of Utah, Salt Lake City, Utah.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Utah</region>
</placeName>
<wicri:cityArea>Department of Medicine, University of Utah, Salt Lake City</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Safdar, Zeenat" sort="Safdar, Zeenat" uniqKey="Safdar Z" first="Zeenat" last="Safdar">Zeenat Safdar</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Baylor College of Medicine, Houston, Texas.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>Department of Medicine, Baylor College of Medicine, Houston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Ventetuolo, Corey E" sort="Ventetuolo, Corey E" uniqKey="Ventetuolo C" first="Corey E" last="Ventetuolo">Corey E. Ventetuolo</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine and Health Services, Policy and Practice, Brown University, Providence, Rhode Island; and.</nlm:affiliation>
<orgName type="university">Université Brown</orgName>
<country>États-Unis</country>
<placeName><settlement type="city">Providence (Rhode Island)</settlement>
<region type="state">Rhode Island</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zamanian, Roham T" sort="Zamanian, Roham T" uniqKey="Zamanian R" first="Roham T" last="Zamanian">Roham T. Zamanian</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, Stanford University, Stanford, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
<settlement type="city">Stanford (Californie)</settlement>
</placeName>
<wicri:cityArea>Department of Medicine, Stanford University, Stanford</wicri:cityArea>
<orgName type="university">Université Stanford</orgName>
</affiliation>
</author>
<author><name sortKey="Leary, Peter J" sort="Leary, Peter J" uniqKey="Leary P" first="Peter J" last="Leary">Peter J. Leary</name>
<affiliation><nlm:affiliation>Department of Medicine and.</nlm:affiliation>
<wicri:noCountry code="no comma">Department of Medicine and.</wicri:noCountry>
<wicri:noCountry code="no comma">Department of Medicine and.</wicri:noCountry>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Department of Epidemiology, University of Washington, Seattle, Washington.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Washington (État)</region>
<settlement type="city">Seattle</settlement>
</placeName>
<wicri:cityArea>Department of Epidemiology, University of Washington, Seattle</wicri:cityArea>
<orgName type="university">Université de Washington</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">Annals of the American Thoracic Society</title>
<idno type="eISSN">2325-6621</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine Monophosphate (analogs & derivatives)</term>
<term>Adenosine Monophosphate (therapeutic use)</term>
<term>Adrenal Cortex Hormones (therapeutic use)</term>
<term>Alanine (analogs & derivatives)</term>
<term>Alanine (therapeutic use)</term>
<term>Antibodies, Monoclonal, Humanized (therapeutic use)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Azithromycin (therapeutic use)</term>
<term>COVID-19 (drug therapy)</term>
<term>COVID-19 (epidemiology)</term>
<term>COVID-19 (therapy)</term>
<term>Cardiac Catheterization (statistics & numerical data)</term>
<term>Chloroquine (therapeutic use)</term>
<term>Chronic Disease (MeSH)</term>
<term>Computed Tomography Angiography (statistics & numerical data)</term>
<term>Delivery of Health Care (MeSH)</term>
<term>Echocardiography (statistics & numerical data)</term>
<term>Hospital Mortality (MeSH)</term>
<term>Hospitalization (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Hypertension, Pulmonary (diagnosis)</term>
<term>Hypertension, Pulmonary (epidemiology)</term>
<term>Hypertension, Pulmonary (etiology)</term>
<term>Hypertension, Pulmonary (therapy)</term>
<term>Immunization, Passive (MeSH)</term>
<term>Incidence (MeSH)</term>
<term>Intensive Care Units (MeSH)</term>
<term>Pulmonary Arterial Hypertension (diagnosis)</term>
<term>Pulmonary Arterial Hypertension (epidemiology)</term>
<term>Pulmonary Arterial Hypertension (therapy)</term>
<term>Pulmonary Embolism (complications)</term>
<term>Pulmonary Embolism (diagnosis)</term>
<term>Pulmonary Embolism (epidemiology)</term>
<term>Pulmonary Embolism (therapy)</term>
<term>Surveys and Questionnaires (MeSH)</term>
<term>Telemedicine (statistics & numerical data)</term>
<term>United States (epidemiology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>AMP (analogues et dérivés)</term>
<term>AMP (usage thérapeutique)</term>
<term>Alanine (analogues et dérivés)</term>
<term>Alanine (usage thérapeutique)</term>
<term>Angiographie par tomodensitométrie (statistiques et données numériques)</term>
<term>Anticorps monoclonaux humanisés (usage thérapeutique)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Azithromycine (usage thérapeutique)</term>
<term>Cathétérisme cardiaque (statistiques et données numériques)</term>
<term>Chloroquine (usage thérapeutique)</term>
<term>Embolie pulmonaire (complications)</term>
<term>Embolie pulmonaire (diagnostic)</term>
<term>Embolie pulmonaire (thérapie)</term>
<term>Embolie pulmonaire (épidémiologie)</term>
<term>Enquêtes et questionnaires (MeSH)</term>
<term>Hormones corticosurrénaliennes (usage thérapeutique)</term>
<term>Hospitalisation (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Hypertension pulmonaire (diagnostic)</term>
<term>Hypertension pulmonaire (thérapie)</term>
<term>Hypertension pulmonaire (épidémiologie)</term>
<term>Hypertension pulmonaire (étiologie)</term>
<term>Immunisation passive (MeSH)</term>
<term>Incidence (MeSH)</term>
<term>Maladie chronique (MeSH)</term>
<term>Mortalité hospitalière (MeSH)</term>
<term>Prestations des soins de santé (MeSH)</term>
<term>Télémédecine (statistiques et données numériques)</term>
<term>Unités de soins intensifs (MeSH)</term>
<term>Échocardiographie (statistiques et données numériques)</term>
<term>États-Unis (épidémiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine Monophosphate</term>
<term>Alanine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adenosine Monophosphate</term>
<term>Adrenal Cortex Hormones</term>
<term>Alanine</term>
<term>Antibodies, Monoclonal, Humanized</term>
<term>Antiviral Agents</term>
<term>Azithromycin</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>United States</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>AMP</term>
<term>Alanine</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Pulmonary Embolism</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Hypertension, Pulmonary</term>
<term>Pulmonary Arterial Hypertension</term>
<term>Pulmonary Embolism</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Embolie pulmonaire</term>
<term>Hypertension pulmonaire</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>COVID-19</term>
<term>Hypertension, Pulmonary</term>
<term>Pulmonary Arterial Hypertension</term>
<term>Pulmonary Embolism</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Hypertension, Pulmonary</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Cardiac Catheterization</term>
<term>Computed Tomography Angiography</term>
<term>Echocardiography</term>
<term>Telemedicine</term>
</keywords>
<keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Angiographie par tomodensitométrie</term>
<term>Cathétérisme cardiaque</term>
<term>Télémédecine</term>
<term>Échocardiographie</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>COVID-19</term>
<term>Hypertension, Pulmonary</term>
<term>Pulmonary Arterial Hypertension</term>
<term>Pulmonary Embolism</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Embolie pulmonaire</term>
<term>Hypertension pulmonaire</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>AMP</term>
<term>Alanine</term>
<term>Anticorps monoclonaux humanisés</term>
<term>Antiviraux</term>
<term>Azithromycine</term>
<term>Chloroquine</term>
<term>Embolie pulmonaire</term>
<term>Hormones corticosurrénaliennes</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Embolie pulmonaire</term>
<term>Hypertension pulmonaire</term>
<term>États-Unis</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Hypertension pulmonaire</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Chronic Disease</term>
<term>Delivery of Health Care</term>
<term>Hospital Mortality</term>
<term>Hospitalization</term>
<term>Humans</term>
<term>Immunization, Passive</term>
<term>Incidence</term>
<term>Intensive Care Units</term>
<term>Surveys and Questionnaires</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Enquêtes et questionnaires</term>
<term>Hospitalisation</term>
<term>Humains</term>
<term>Immunisation passive</term>
<term>Incidence</term>
<term>Maladie chronique</term>
<term>Mortalité hospitalière</term>
<term>Prestations des soins de santé</term>
<term>Unités de soins intensifs</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><b>Rationale:</b>
Patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) typically undergo frequent clinical evaluation. The incidence and outcomes of coronavirus disease (COVID-19) and its impact on routine management for patients with pulmonary vascular disease is currently unknown.<b>Objectives:</b>
To assess the cumulative incidence and outcomes of <i>recognized</i>
COVID-19 for patients with PAH/CTEPH followed at accredited pulmonary hypertension centers, and to evaluate the pandemic's impact on clinic operations at these centers.<b>Methods:</b>
A survey was e-mailed to program directors of centers accredited by the Pulmonary Hypertension Association. Descriptive analyses and linear regression were used to analyze results.<b>Results:</b>
Seventy-seven center directors were successfully e-mailed a survey, and 58 responded (75%). The cumulative incidence of COVID-19 recognized in individuals with PAH/CTEPH was 2.9 cases per 1,000 patients, similar to the general U.S. population. In patients with PAH/CTEPH for whom COVID-19 was recognized, 30% were hospitalized and 12% died. These outcomes appear worse than the general population. A large impact on clinic operations was observed including fewer clinic visits and substantially increased use of telehealth. A majority of centers curtailed diagnostic testing and a minority limited new starts of medical therapy. Most centers did not use experimental therapies in patients with PAH/CTEPH diagnosed with COVID-19.<b>Conclusions:</b>
The cumulative incidence of COVID-19 recognized in patients with PAH/CTEPH appears similar to the broader population, although outcomes may be worse. Although the total number of patients with PAH/CTEPH recognized to have COVID-19 was small, the impact of COVID-19 on broader clinic operations, testing, and treatment was substantial.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32726561</PMID>
<DateCompleted><Year>2020</Year>
<Month>12</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>03</Month>
<Day>05</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2325-6621</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>17</Volume>
<Issue>12</Issue>
<PubDate><Year>2020</Year>
<Month>12</Month>
</PubDate>
</JournalIssue>
<Title>Annals of the American Thoracic Society</Title>
<ISOAbbreviation>Ann Am Thorac Soc</ISOAbbreviation>
</Journal>
<ArticleTitle>A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care.</ArticleTitle>
<Pagination><MedlinePgn>1576-1582</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1513/AnnalsATS.202005-521OC</ELocationID>
<Abstract><AbstractText><b>Rationale:</b>
Patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) typically undergo frequent clinical evaluation. The incidence and outcomes of coronavirus disease (COVID-19) and its impact on routine management for patients with pulmonary vascular disease is currently unknown.<b>Objectives:</b>
To assess the cumulative incidence and outcomes of <i>recognized</i>
COVID-19 for patients with PAH/CTEPH followed at accredited pulmonary hypertension centers, and to evaluate the pandemic's impact on clinic operations at these centers.<b>Methods:</b>
A survey was e-mailed to program directors of centers accredited by the Pulmonary Hypertension Association. Descriptive analyses and linear regression were used to analyze results.<b>Results:</b>
Seventy-seven center directors were successfully e-mailed a survey, and 58 responded (75%). The cumulative incidence of COVID-19 recognized in individuals with PAH/CTEPH was 2.9 cases per 1,000 patients, similar to the general U.S. population. In patients with PAH/CTEPH for whom COVID-19 was recognized, 30% were hospitalized and 12% died. These outcomes appear worse than the general population. A large impact on clinic operations was observed including fewer clinic visits and substantially increased use of telehealth. A majority of centers curtailed diagnostic testing and a minority limited new starts of medical therapy. Most centers did not use experimental therapies in patients with PAH/CTEPH diagnosed with COVID-19.<b>Conclusions:</b>
The cumulative incidence of COVID-19 recognized in patients with PAH/CTEPH appears similar to the broader population, although outcomes may be worse. Although the total number of patients with PAH/CTEPH recognized to have COVID-19 was small, the impact of COVID-19 on broader clinic operations, testing, and treatment was substantial.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName>
<ForeName>Joshua D</ForeName>
<Initials>JD</Initials>
<Identifier Source="ORCID">0000-0001-7715-2107</Identifier>
<AffiliationInfo><Affiliation>Department of Medicine and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Burger</LastName>
<ForeName>Charles D</ForeName>
<Initials>CD</Initials>
<AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Mayo Clinic Florida, Jacksonville, Florida.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Delossantos</LastName>
<ForeName>Genecelle B</ForeName>
<Initials>GB</Initials>
<AffiliationInfo><Affiliation>Department of Medicine and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Grinnan</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, Virginia Commonwealth University, Richmond, Virginia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ralph</LastName>
<ForeName>David D</ForeName>
<Initials>DD</Initials>
<AffiliationInfo><Affiliation>Department of Medicine and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rayner</LastName>
<ForeName>Sam G</ForeName>
<Initials>SG</Initials>
<AffiliationInfo><Affiliation>Department of Medicine and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ryan</LastName>
<ForeName>John J</ForeName>
<Initials>JJ</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, University of Utah, Salt Lake City, Utah.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Safdar</LastName>
<ForeName>Zeenat</ForeName>
<Initials>Z</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, Baylor College of Medicine, Houston, Texas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ventetuolo</LastName>
<ForeName>Corey E</ForeName>
<Initials>CE</Initials>
<AffiliationInfo><Affiliation>Department of Medicine and Health Services, Policy and Practice, Brown University, Providence, Rhode Island; and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zamanian</LastName>
<ForeName>Roham T</ForeName>
<Initials>RT</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, Stanford University, Stanford, California.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Leary</LastName>
<ForeName>Peter J</ForeName>
<Initials>PJ</Initials>
<Identifier Source="ORCID">0000-0001-5716-248X</Identifier>
<AffiliationInfo><Affiliation>Department of Medicine and.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Epidemiology, University of Washington, Seattle, Washington.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Ann Am Thorac Soc</MedlineTA>
<NlmUniqueID>101600811</NlmUniqueID>
<ISSNLinking>2325-6621</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber>
<NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>415SHH325A</RegistryNumber>
<NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>83905-01-5</RegistryNumber>
<NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>I031V2H011</RegistryNumber>
<NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber>
<NameOfSubstance UI="D000409">Alanine</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
<SupplMeshName Type="Protocol" UI="C000705128">COVID-19 serotherapy</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Ann Am Thorac Soc. 2020 Dec;17(12):1528-1530</RefSource>
<PMID Version="1">33258672</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006328" MajorTopicYN="N">Cardiac Catheterization</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000072226" MajorTopicYN="N">Computed Tomography Angiography</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003695" MajorTopicYN="N">Delivery of Health Care</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006976" MajorTopicYN="N">Hypertension, Pulmonary</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000081029" MajorTopicYN="N">Pulmonary Arterial Hypertension</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017216" MajorTopicYN="N">Telemedicine</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword>
<Keyword MajorTopicYN="Y">clinic operations</Keyword>
<Keyword MajorTopicYN="Y">outcomes</Keyword>
<Keyword MajorTopicYN="Y">telehealth</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>7</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>12</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>7</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32726561</ArticleId>
<ArticleId IdType="doi">10.1513/AnnalsATS.202005-521OC</ArticleId>
<ArticleId IdType="pmc">PMC7706604</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Ther Adv Chronic Dis. 2017 Feb;8(2-3):47-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28348727</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2020 Jul;20(7):776-777</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32224313</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32298251</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 May 26;323(20):2052-2059</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32320003</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Control Hosp Epidemiol. 2016 Nov;37(11):1272-1277</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27514583</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Epidemiology. 2020 Jul;31(4):567-569</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32324625</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2020 May;94:91-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32173574</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Appl Health Econ Health Policy. 2011 Sep 1;9(5):293-303</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21875160</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Fam Pract. 2019 Jul 3;20(1):92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31269902</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pulm Circ. 2020 Apr 29;10(2):2045894020920153</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32426111</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Appl Health Econ Health Policy. 2011 Nov 1;9(6):377-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21888449</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 21;323(15):1499-1500</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32159735</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2020 Jul;20(7):773</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171390</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Acad Emerg Med. 2020 Mar 24;8(1):e35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32232218</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chest. 2011 Mar;139(3):497-504</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20724737</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Coll Surg. 2020 Aug;231(2):216-222.e2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32360960</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pulm Circ. 2020 Apr 27;10(2):2045894020922799</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32426113</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Respir J. 2015 Oct;46(4):903-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26318161</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Contemp Clin Trials Commun. 2015 Dec 30;2:54-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29736446</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Coll Cardiol. 2020 May 12;75(18):2372-2375</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32199938</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Heart Lung Transplant. 2020 Jul;39(7):729-730</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32360293</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2009 Jul 9;361(2):112-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19474417</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cardiol Clin. 2016 Aug;34(3):489-500</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27443143</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Californie</li>
<li>Floride</li>
<li>Rhode Island</li>
<li>Texas</li>
<li>Utah</li>
<li>Virginie</li>
<li>Washington (État)</li>
</region>
<settlement><li>Providence (Rhode Island)</li>
<li>Seattle</li>
<li>Stanford (Californie)</li>
</settlement>
<orgName><li>Université Brown</li>
<li>Université Stanford</li>
<li>Université de Washington</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Delossantos, Genecelle B" sort="Delossantos, Genecelle B" uniqKey="Delossantos G" first="Genecelle B" last="Delossantos">Genecelle B. Delossantos</name>
<name sortKey="Lee, Joshua D" sort="Lee, Joshua D" uniqKey="Lee J" first="Joshua D" last="Lee">Joshua D. Lee</name>
<name sortKey="Ralph, David D" sort="Ralph, David D" uniqKey="Ralph D" first="David D" last="Ralph">David D. Ralph</name>
<name sortKey="Rayner, Sam G" sort="Rayner, Sam G" uniqKey="Rayner S" first="Sam G" last="Rayner">Sam G. Rayner</name>
</noCountry>
<country name="États-Unis"><region name="Floride"><name sortKey="Burger, Charles D" sort="Burger, Charles D" uniqKey="Burger C" first="Charles D" last="Burger">Charles D. Burger</name>
</region>
<name sortKey="Grinnan, Daniel" sort="Grinnan, Daniel" uniqKey="Grinnan D" first="Daniel" last="Grinnan">Daniel Grinnan</name>
<name sortKey="Leary, Peter J" sort="Leary, Peter J" uniqKey="Leary P" first="Peter J" last="Leary">Peter J. Leary</name>
<name sortKey="Ryan, John J" sort="Ryan, John J" uniqKey="Ryan J" first="John J" last="Ryan">John J. Ryan</name>
<name sortKey="Safdar, Zeenat" sort="Safdar, Zeenat" uniqKey="Safdar Z" first="Zeenat" last="Safdar">Zeenat Safdar</name>
<name sortKey="Ventetuolo, Corey E" sort="Ventetuolo, Corey E" uniqKey="Ventetuolo C" first="Corey E" last="Ventetuolo">Corey E. Ventetuolo</name>
<name sortKey="Zamanian, Roham T" sort="Zamanian, Roham T" uniqKey="Zamanian R" first="Roham T" last="Zamanian">Roham T. Zamanian</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A04 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001A04 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:32726561 |texte= A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32726561" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
This area was generated with Dilib version V0.6.38. |